Heparin Sodium Panpharma (Heparin Sodium)

Heparin Sodium Panpharma is indicated for several antithrombotic indications where rapid anticoagulation is required.

• Prevention and treatment of deep vein thrombosis (DVT) and its complications.
• Prevention and treatment of pulmonary embolism (PE).
• Anticoagulation during cardiac surgery, cardiopulmonary bypass, and other invasive procedures.
• Management of acute coronary syndromes, including unstable angina and non‑ST‑segment elevation myocardial infarction.
• Prophylaxis of clot formation in patients with high risk of thrombosis, such as those immobilized after major surgery.

Adverse reactions to Heparin Sodium Panpharma vary in frequency and severity.

Common

• Minor bleeding at the injection site or mild epistaxis.
• Localized bruising or hematoma formation.
• Transient elevation of liver enzymes.
• Mild thrombocytopenia without clinical sequelae.

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Spontaneous spinal or epidural hematoma leading to neurologic compromise.

Before initiating therapy with Heparin Sodium Panpharma, clinicians should evaluate several safety considerations.

• Assess baseline coagulation parameters and platelet count.
• Review patient history for recent surgery, trauma, or active bleeding.
• Use caution in patients with renal or hepatic impairment.
• Avoid use in individuals with known hypersensitivity to heparin or pork‑derived products.
• Monitor for signs of heparin‑induced thrombocytopenia during treatment.
• Adjust dose in obese or underweight patients based on weight‑based protocols.
• Consider pregnancy status, as safety data are limited.

Heparin Sodium Panpharma may interact with other agents that affect hemostasis or drug metabolism.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) or antiplatelet drugs (e.g., aspirin, clopidogrel) without dose adjustment.
• High‑dose fibrinolytic therapy (e.g., alteplase) due to additive bleeding risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that impair platelet function.

Use with caution

• Thrombolytic agents administered in separate therapeutic windows.
• Drugs that reduce platelet count (e.g., chemotherapy agents) increasing HIT risk.
• Medications that bind plasma proteins and may alter heparin activity (e.g., protamine reversal agents).